Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path"), a biotechnology
company developing a liposomal delivery technology for nucleic acid
cancer drugs, today announced that Peter Nielsen, President and Chief
Executive Officer, will present a company overview at the Biotech
Showcase™ 2014 Conference in San Francisco, Calif., on Wednesday,
January 15, 2014 at 8:00 a.m. Pacific Time.
A webcast of Mr. Nielsen's remarks will be available live. You
can access the webcast at the Company's website: www.biopathholdings.com.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic
products utilizing its proprietary liposomal delivery technology
designed to systemically distribute nucleic acid drugs throughout the
human body with a simple intravenous transfusion. Bio-Path's lead
product candidate, Liposomal Grb-2, is in a Phase I study for blood
cancers and in preclinical studies for triple negative and inflammatory
breast cancers. Bio-Path's second drug candidate, also a liposomal
antisense drug, is ready for the clinic where it will be evaluated in
lymphoma and solid tumors.
Any statements that are not historical facts contained in this
release are forward-looking statements that involve risks and
uncertainties, including Bio-Path's ability to raise needed additional
capital on a timely basis in order for it to continue its operations,
have success in the clinical development of its technologies, the timing
of enrollment and release of data in such clinical studies and the
accuracy of such data, limited patient populations of early stage
clinical studies and the possibility that results from later stage
clinical trials with much larger patient populations may not be
consistent with earlier stage clinical trials, and such other risks
which are identified in the Company's most recent Annual Report on Form
10-K and in any subsequent quarterly reports on Form 10-Q. These
documents are available on request from Bio-Path Holdings or at www.sec.gov.
Bio-Path disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For more information, please visit the Company's website at http://www.biopathholdings.com.
[ Back To NFVZone's Homepage ]